Report Detail
Global Dyslipidemia Drugs Market Professional Survey Report 2019
- RnM3720733 |
- 03 September, 2019 |
- Global |
- 123 Pages |
- QYResearch |
- Pharma & Healthcare
Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.
The increasing risk of cardiovascular disease (CVDs) is the primary driver for the market’s growth. Elevated cholesterol levels account for nearly one-third of the total ischemic heart diseases and persist as a substantial cause of ischemic heart diseases and strokes in emerging countries such as India and China. Thus, the cardiovascular risk management guidelines set by authorities such as the American College of Cardiology and American Heart Association acknowledge the decreasing the blood cholesterol as a prime factor in cutting down on the cardiovascular risks. This, in turn, drives the cholesterol maintaining drugs to avoid CVDs risk and boosting the sales of the drugs market.
With the presence of numerous small and larger vendors, the global dyslipidemia drugs market is largely competitive. Competition is observed from the regional players globally, and there are numerous new manufacturers entering the market. Moreover, companies like Amgen, HanAll BioPharma, Kowa Pharmaceuticals, CJ HealthCare, Catabasis Pharmaceuticals, JW Pharmaceuticals, and Esperion Pharmaceuticals are expected to enter the market over the next four years.
The global Dyslipidemia Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Dyslipidemia Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dyslipidemia Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Dyslipidemia Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Dyslipidemia Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
AstraZeneca
Merck
Pfizer
Sanofi
Alnylam Pharmaceuticals
Amarin Corporation
Amgen
Bristol-Myers Squibb
Catabasis Pharmaceuticals
Cerenis
Cipla
CJ HealthCare
CKD Bio
Daewoong Pharmaceutical
Daiichi Sankyo
Eli Lilly
Esperion Therapeutics
GlaxoSmithKline
JW Pharmaceuticals
Kadmon Pharmaceuticals
Lupin Pharmaceuticals
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Statins
Cholesterol absorption inhibitors
Dyslipidemia injectable
Segment by Application
Hospitals and Clinics
Medical Laboratories
Drug Stores
Others
Table of Contents
Executive Summary
1 Industry Overview of Dyslipidemia Drugs
- 1.1 Definition of Dyslipidemia Drugs
- 1.2 Dyslipidemia Drugs Segment by Type
- 1.2.1 Global Dyslipidemia Drugs Production Growth Rate Comparison by Types (2014-2025)
- 1.2.2 Statins
- 1.2.3 Cholesterol absorption inhibitors
- 1.2.4 Dyslipidemia injectable
- 1.3 Dyslipidemia Drugs Segment by Applications
- 1.3.1 Global Dyslipidemia Drugs Consumption Comparison by Applications (2014-2025)
- 1.3.2 Hospitals and Clinics
- 1.3.3 Medical Laboratories
- 1.3.4 Drug Stores
- 1.3.5 Others
- 1.4 Global Dyslipidemia Drugs Overall Market
- 1.4.1 Global Dyslipidemia Drugs Revenue (2014-2025)
- 1.4.2 Global Dyslipidemia Drugs Production (2014-2025)
- 1.4.3 North America Dyslipidemia Drugs Status and Prospect (2014-2025)
- 1.4.4 Europe Dyslipidemia Drugs Status and Prospect (2014-2025)
- 1.4.5 China Dyslipidemia Drugs Status and Prospect (2014-2025)
- 1.4.6 Japan Dyslipidemia Drugs Status and Prospect (2014-2025)
- 1.4.7 Southeast Asia Dyslipidemia Drugs Status and Prospect (2014-2025)
- 1.4.8 India Dyslipidemia Drugs Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
- 2.1 Raw Material and Suppliers
- 2.2 Manufacturing Cost Structure Analysis of Dyslipidemia Drugs
- 2.3 Manufacturing Process Analysis of Dyslipidemia Drugs
- 2.4 Industry Chain Structure of Dyslipidemia Drugs
3 Development and Manufacturing Plants Analysis of Dyslipidemia Drugs
- 3.1 Capacity and Commercial Production Date
- 3.2 Global Dyslipidemia Drugs Manufacturing Plants Distribution
- 3.3 Major Manufacturers Technology Source and Market Position of Dyslipidemia Drugs
- 3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
- 4.1 Dyslipidemia Drugs Production and Capacity Analysis
- 4.2 Dyslipidemia Drugs Revenue Analysis
- 4.3 Dyslipidemia Drugs Price Analysis
- 4.4 Market Concentration Degree
5 Dyslipidemia Drugs Regional Market Analysis
- 5.1 Dyslipidemia Drugs Production by Regions
- 5.1.1 Global Dyslipidemia Drugs Production by Regions
- 5.1.2 Global Dyslipidemia Drugs Revenue by Regions
- 5.2 Dyslipidemia Drugs Consumption by Regions
- 5.3 North America Dyslipidemia Drugs Market Analysis
- 5.3.1 North America Dyslipidemia Drugs Production
- 5.3.2 North America Dyslipidemia Drugs Revenue
- 5.3.3 Key Manufacturers in North America
- 5.3.4 North America Dyslipidemia Drugs Import and Export
- 5.4 Europe Dyslipidemia Drugs Market Analysis
- 5.4.1 Europe Dyslipidemia Drugs Production
- 5.4.2 Europe Dyslipidemia Drugs Revenue
- 5.4.3 Key Manufacturers in Europe
- 5.4.4 Europe Dyslipidemia Drugs Import and Export
- 5.5 China Dyslipidemia Drugs Market Analysis
- 5.5.1 China Dyslipidemia Drugs Production
- 5.5.2 China Dyslipidemia Drugs Revenue
- 5.5.3 Key Manufacturers in China
- 5.5.4 China Dyslipidemia Drugs Import and Export
- 5.6 Japan Dyslipidemia Drugs Market Analysis
- 5.6.1 Japan Dyslipidemia Drugs Production
- 5.6.2 Japan Dyslipidemia Drugs Revenue
- 5.6.3 Key Manufacturers in Japan
- 5.6.4 Japan Dyslipidemia Drugs Import and Export
- 5.7 Southeast Asia Dyslipidemia Drugs Market Analysis
- 5.7.1 Southeast Asia Dyslipidemia Drugs Production
- 5.7.2 Southeast Asia Dyslipidemia Drugs Revenue
- 5.7.3 Key Manufacturers in Southeast Asia
- 5.7.4 Southeast Asia Dyslipidemia Drugs Import and Export
- 5.8 India Dyslipidemia Drugs Market Analysis
- 5.8.1 India Dyslipidemia Drugs Production
- 5.8.2 India Dyslipidemia Drugs Revenue
- 5.8.3 Key Manufacturers in India
- 5.8.4 India Dyslipidemia Drugs Import and Export
6 Dyslipidemia Drugs Segment Market Analysis (by Type)
- 6.1 Global Dyslipidemia Drugs Production by Type
- 6.2 Global Dyslipidemia Drugs Revenue by Type
- 6.3 Dyslipidemia Drugs Price by Type
7 Dyslipidemia Drugs Segment Market Analysis (by Application)
- 7.1 Global Dyslipidemia Drugs Consumption by Application
- 7.2 Global Dyslipidemia Drugs Consumption Market Share by Application (2014-2019)
8 Dyslipidemia Drugs Major Manufacturers Analysis
- 8.1 AstraZeneca
- 8.1.1 AstraZeneca Dyslipidemia Drugs Production Sites and Area Served
- 8.1.2 AstraZeneca Product Introduction, Application and Specification
- 8.1.3 AstraZeneca Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.1.4 Main Business and Markets Served
- 8.2 Merck
- 8.2.1 Merck Dyslipidemia Drugs Production Sites and Area Served
- 8.2.2 Merck Product Introduction, Application and Specification
- 8.2.3 Merck Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.2.4 Main Business and Markets Served
- 8.3 Pfizer
- 8.3.1 Pfizer Dyslipidemia Drugs Production Sites and Area Served
- 8.3.2 Pfizer Product Introduction, Application and Specification
- 8.3.3 Pfizer Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.3.4 Main Business and Markets Served
- 8.4 Sanofi
- 8.4.1 Sanofi Dyslipidemia Drugs Production Sites and Area Served
- 8.4.2 Sanofi Product Introduction, Application and Specification
- 8.4.3 Sanofi Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.4.4 Main Business and Markets Served
- 8.5 Alnylam Pharmaceuticals
- 8.5.1 Alnylam Pharmaceuticals Dyslipidemia Drugs Production Sites and Area Served
- 8.5.2 Alnylam Pharmaceuticals Product Introduction, Application and Specification
- 8.5.3 Alnylam Pharmaceuticals Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.5.4 Main Business and Markets Served
- 8.6 Amarin Corporation
- 8.6.1 Amarin Corporation Dyslipidemia Drugs Production Sites and Area Served
- 8.6.2 Amarin Corporation Product Introduction, Application and Specification
- 8.6.3 Amarin Corporation Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.6.4 Main Business and Markets Served
- 8.7 Amgen
- 8.7.1 Amgen Dyslipidemia Drugs Production Sites and Area Served
- 8.7.2 Amgen Product Introduction, Application and Specification
- 8.7.3 Amgen Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.7.4 Main Business and Markets Served
- 8.8 Bristol-Myers Squibb
- 8.8.1 Bristol-Myers Squibb Dyslipidemia Drugs Production Sites and Area Served
- 8.8.2 Bristol-Myers Squibb Product Introduction, Application and Specification
- 8.8.3 Bristol-Myers Squibb Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.8.4 Main Business and Markets Served
- 8.9 Catabasis Pharmaceuticals
- 8.9.1 Catabasis Pharmaceuticals Dyslipidemia Drugs Production Sites and Area Served
- 8.9.2 Catabasis Pharmaceuticals Product Introduction, Application and Specification
- 8.9.3 Catabasis Pharmaceuticals Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.9.4 Main Business and Markets Served
- 8.10 Cerenis
- 8.10.1 Cerenis Dyslipidemia Drugs Production Sites and Area Served
- 8.10.2 Cerenis Product Introduction, Application and Specification
- 8.10.3 Cerenis Dyslipidemia Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.10.4 Main Business and Markets Served
- 8.11 Cipla
- 8.12 CJ HealthCare
- 8.13 CKD Bio
- 8.14 Daewoong Pharmaceutical
- 8.15 Daiichi Sankyo
- 8.16 Eli Lilly
- 8.17 Esperion Therapeutics
- 8.18 GlaxoSmithKline
- 8.19 JW Pharmaceuticals
- 8.20 Kadmon Pharmaceuticals
- 8.21 Lupin Pharmaceuticals
9 Development Trend of Analysis of Dyslipidemia Drugs Market
- 9.1 Global Dyslipidemia Drugs Market Trend Analysis
- 9.1.1 Global Dyslipidemia Drugs Market Size (Volume and Value) Forecast 2019-2025
- 9.2 Dyslipidemia Drugs Regional Market Trend
- 9.2.1 North America Dyslipidemia Drugs Forecast 2019-2025
- 9.2.2 Europe Dyslipidemia Drugs Forecast 2019-2025
- 9.2.3 China Dyslipidemia Drugs Forecast 2019-2025
- 9.2.4 Japan Dyslipidemia Drugs Forecast 2019-2025
- 9.2.5 Southeast Asia Dyslipidemia Drugs Forecast 2019-2025
- 9.2.6 India Dyslipidemia Drugs Forecast 2019-2025
- 9.3 Dyslipidemia Drugs Market Trend (Product Type)
- 9.4 Dyslipidemia Drugs Market Trend (Application)
- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.3 Dyslipidemia Drugs Customers
11 Market Dynamics
- 11.1 Market Trends
- 11.2 Opportunities
- 11.3 Market Drivers
- 11.4 Challenges
- 11.5 Influence Factors
12 Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Dyslipidemia Drugs. Industry analysis & Market Report on Dyslipidemia Drugs is a syndicated market report, published as Global Dyslipidemia Drugs Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Dyslipidemia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
